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The accumulation of amyloid-b (Ab) as amyloid fibrils
and toxic oligomers is an important step in the devel-
opment of Alzheimer’s disease (AD). However, there
are numerous potentially toxic oligomers and little is
known about their neurological effects when gener-
ated in the living brain. Here we show that Ab oligo-
mers can be assigned to one of at least two classes
(type 1 and type 2) based on their temporal, spatial,
and structural relationships to amyloid fibrils. The
type 2 oligomers are related to amyloid fibrils and
represent themajority of oligomers generated in vivo,
but they remain confined to the vicinity of amyloid
plaques and do not impair cognition at levels relevant
to AD. Type 1 oligomers are unrelated to amyloid fi-
brils and may have greater potential to cause global
neural dysfunction in ADbecause they are dispersed.
These results refine our understanding of the patho-
genicity of Ab oligomers in vivo.INTRODUCTION
Alzheimer’s disease (AD) is believed to be caused by neuro-
toxic assemblies of the amyloid-b (Ab) peptide. Distinct assem-
blies of Ab have been found in the human brain, including
amyloid fibrils and a few specific oligomers (Lasagna-Reeves
et al., 2011; Lesne´ et al., 2013; Lu et al., 2013; Noguchi
et al., 2009; Shankar et al., 2008). It is widely accepted that
Ab oligomers (Abo) are more potent neurotoxins than amyloid
fibrils, and several oligomers have been isolated and studied
in detail. These oligomers differ in size and, to varying degrees,1760 Cell Reports 11, 1760–1771, June 23, 2015 ª2015 The Authorsin their temporal and spatial patterns of expression, association
with other brain proteins, and effects on neuronal function and
viability (Lasagna-Reeves et al., 2011; Lesne´ et al., 2006, 2013;
Noguchi et al., 2009; Shankar et al., 2008). However, there is
no general consensus as to which oligomers are the most
significant in the pathophysiology of AD nor, indeed, on the
total number of Abo types produced in the brain (reviewed in
Benilova et al., 2012). The diversity of form and function among
the Abo studied thus far, and the likely existence of an inde-
terminate number of other Abo, makes the isolation and func-
tional characterization of all potential forms a laborious, if not
impossible, task. In an attempt to resolve this predicament,
we asked whether Abo generated in vivo could be categorized
according to their spatiotemporal patterns of expression and
structural features as inferred from their reactivity with confor-
mation-selective antibodies, and, if so, whether the different
classes of oligomers exert different pathological effects on neu-
ral function.
Studies using conformation-selective antibodies have identi-
fied at least two classes of oligomers that are generated
in vitro and in the brains of AD patients and amyloid precursor
protein (APP) transgenic mice (Glabe, 2008). The OC and A11
conformation-selective antibodies detect mutually exclusive
structural epitopes of amyloid-forming proteins, independent
of primary amino acid sequence (Kayed et al., 2007; Wu et al.,
2010). OC antibodies recognize Ab amyloid fibrils as well as
Abo (Kayed et al., 2007); it has been suggested, but never
directly demonstrated, that OC detects in-register parallel b
sheets (Glabe, 2009; Wu et al., 2010). Conversely, A11 anti-
bodies have been shown to recognize out-of-register anti-paral-
lel b sheet structures (Laganowsky et al., 2012; Liu et al., 2012).
Our objective in the current work was to address the following
questions related to Abo generated in vivo: (1) are there distinct
subtypes of Abo based on quaternary structural motifs, as
Figure 1. OC Antibodies Recognize In-
Register Parallel b Sheet Structures
(A and B) Transmission electron micrographs
show D23N_Ab40 fibrils with (A) in-register parallel
b sheet structure and (B) anti-parallel structure.
(C) 13C-PITHIRDs-CT decay curves for parallel
and anti-parallel fibrils with 13C labeling at
Ala21-13Cʹ. Theoretical decay curves with 4.7 and
9.8 A˚ 13C-13C distances are shown as dotted lines.
Experimental data for the parallel and anti-parallel
fibrils are indicated by circles and squares,
respectively. The error bars (SEM) were deter-
mined from the experimental spectral noise.
(D) (Left) Dot blot shows that OC antibodies
selectively detect D23N_Ab40 fibrils with in-
register parallel b sheet structure. (Right) Blot
shown at left was stripped and re-probed with
monoclonal antibody 6E10 to confirm that
approximately equal amounts of parallel and anti-
parallel fibrils were loaded. Scale bars (A and B),
100 nm. See also Figure S1.defined by their reactivity with OC and A11 antibodies; (2) do
OC- and A11-reactive oligomers differ in their spatial and tempo-
ral patterns of appearance; and (3) what is the most abundant
type of Abo produced in the brain and how does it affect neuro-
logical function?
To address these questions, we employed transgenic mice
expressing APP variants linked to AD. The types of Abo (e.g.,
Ab dimers and Ab*56, a putative dodecamer) and fibrils in
mice vary dynamically, over a timescale of weeks to months
(for examples in Tg2576, Arc6, and hAPP-J20 mice, see Cheng
et al., 2007; Lesne´ et al., 2006; and Shankar et al., 2009). In the
lines that have been characterized, the sequence of appear-
ance of specific Ab assemblies is consistent. Here we studied
four lines of transgenic mice. In Tg2576 (Hsiao et al., 1996),
hAPP-J20 (Cheng et al., 2007), and TetO-APPSweInd mice
(Jankowsky et al., 2005), the A11-reactive oligomer Ab*56
appeared in young mice 3–6 months prior to dense-core
plaques and correlated with spatial memory deficits (Cheng
et al., 2007; Fowler et al., 2014; Lesne´ et al., 2006). In
rTg9191 mice (Liu et al., 2015), we found dense-core plaques
emerging at 12 months, but no Ab*56 at any age (Liu et al.,
2015).
Here we show that OC antibodies selectively recognized qua-
ternary structural motifs found in naturally occurring Ab amyloid
fibrils, namely in-register parallel b sheets (for review, see Glabe,
2009 and Tycko, 2011). We also show that OC-immunoreactive
Abo appeared only after plaque formation and that they were
highly concentrated around amyloid plaques in the brains of
APP transgenic mice. Conversely, A11-immunoreactive oligo-
mers appeared prior to amyloid plaques in multiple lines ofCell Reports 11, 1760–177APP transgenic mice (here and see also
Cheng et al., 2007; Fowler et al., 2014;
and Lesne´ et al., 2006), and they were
dispersed in the brain parenchyma
without any relationship to amyloid pla-
ques. We classified the Abo generated
in the brains of these APP transgenicmice into two categories: (1) type 1, which has no temporal,
spatial, or structural relationship to amyloid fibrils; and (2) type
2, which is related to amyloid fibrils temporally, spatially, and
structurally.We found that in brains bearing dense-core plaques,
type 2 Abo predominate, consistent with predictions from in vitro
studies (Cohen et al., 2013). However, type 2 Abo appear to have
limited potential to diffuse away from dense-core plaques or to
disrupt forebrain neural networks, as assessed by tests of
cognition.
RESULTS
OC Antibodies Selectively Detect In-Register Parallel b
Sheet Structures
We first sought to more precisely define the structures recog-
nized by OC and A11 antibodies. It was not possible to isolate
from the brains of transgenic mice Abo of sufficient purity or
quantity to perform biophysical characterization of their struc-
tures, so we turned to synthetically prepared Ab fibrils with
defined quaternary structures. It had been suggested that OC
detects in-register parallel b sheets (Glabe, 2009; Wu et al.,
2010), but this hypothesis had not been directly tested. Amyloid
fibrils containing in-register parallel b sheets or anti-parallel b
sheets were prepared from the 40-residue Ab peptide with the
AD-linked Iowa mutation (D23N_Ab40). Transmission electron
microscopy and solid-state nuclear magnetic resonance spec-
troscopy confirmed that these fibrils had the morphological
features of parallel and anti-parallel fibrils whose backbone reg-
istries in the hydrophobic core regions were defined (Qiang et al.,
2012; Sgourakis et al., 2015; Figures 1A–1C). OC antibodies1, June 23, 2015 ª2015 The Authors 1761
Figure 2. Age-Dependent Appearance of
A11- and OC-Immunoreactive Abo
(A–J) Brain sections stained with thioflavin S reveal
dense-core plaques in cerebral cortex. (A–C)
hAPP-J20 (A, non-transgenic, 4 months; B, hAPP-
J20, 4 months; C, hAPP-J20, 12 months); (D–F)
Tg2576 (D, non-transgenic, 9 months; E, Tg2576,
9 months; F, Tg2576, 21 months); (G–I) rTg9191
(G, non-transgenic, 4 months; H, rTg9191,
4 months; I, rTg9191, 24 months); (J) AD brain.
Scale bar in (J), 100 mm, applies to (A–J).
(K) OC-reactive aggregates are seen after the
appearance of dense-core plaques. (Top) Dot
blots show protein aggregates detected by
polyclonal OC antibodies in water-soluble
brain extracts from hAPP-J20, Tg2576, and
rTg9191 mice prior to (hAPP-J20, 4 months;
Tg2576, 9 months; rTg9191, 4 months) and after
(hAPP-J20, 12 months; Tg2576, 21 months;
rTg9191, 24 months) the appearance of dense-
core plaques. Extracts from non-transgenic
littermates (nTg) are shown for comparison.
Synthetic soluble Ab aggregates (syn) with in-
register parallel b sheets (2 ng) were used as a
positive control. (Bottom) a-tubulin served as the
loading control.
(L) A11-reactive aggregates are seen prior to the
appearance of dense-core plaques. (Top) Dot
blots were prepared as in (K) but probed with A11
antibodies. Synthetic Ab40 oligomers (syn) were
prepared as in Kayed et al. (2003). (Bottom)
a-tubulin served as the loading control. See also
Figures S2 and S7.preferentially recognized parallel, over anti-parallel, fibrils in im-
munoblots (Figure 1D).
It also has been suggested that A11 antibodies recognize
structures containing anti-parallel b sheets (Glabe, 2009; Wu
et al., 2010), and A11 indeed reacts with synthetic oligomers
composed of out-of-register anti-parallel b sheets (Laganow-
sky et al., 2012; Liu et al., 2012). We first tested whether
A11 antibodies prefer anti-parallel over parallel b sheets, using
synthetic Ab fibrils. A11 antibodies also detected these
synthetic fibrils, although with less sensitivity than did OC
(Figure S1A). Similar to OC, A11 preferred parallel fibrils to
anti-parallel fibrils. While this result might seem at odds with
the notion of two structurally distinct classes of oligomers, a
potential resolution may be found in Figure S1B. We
compared the A11 signal generated by synthetic Ab fibrils to
the signal generated by Abo in the brains of 4-month-old
hAPP-J20 mice, which lack OC-reactive Ab species (see
below). A much stronger signal was observed from the brain
extracts, estimated to contain 3 pg total Ab, based on semi-
quantitative analysis of Ab in western blots (data not shown)1762 Cell Reports 11, 1760–1771, June 23, 2015 ª2015 The Authorsand previously reported ELISA mea-
surements of Ab levels in hAPP-J20
mice at this age (Cheng et al., 2007),
than from nanogram quantities of the
synthetic Ab fibrils. We concluded that
while A11 can bind amyloid fibrils, it
preferentially recognizes some struc-tural feature of the brain-derived Abo that is not found in fibrils
containing in-register b sheets.
A11 Antibodies Recognize Abo prior to Plaque
Formation, while OC Antibodies Recognize Abo Only
after Plaques Appear
Aqueous extracts were prepared from the brains of Tg2576,
hAPP-J20, and rTg9191 APP transgenic mice at ages prior to
and following the appearance of dense-core plaques (Figures
2A–2J), and they were subjected to immunoblotting under non-
denaturing conditions. OC immunoreactivity was seen only in
extracts from plaque-containing brains in all three lines exam-
ined (Figures 2K and 6A; see also Liu et al., 2015). Conversely,
A11 immunoreactivity appeared prior to plaque deposition in
Tg2576 and hAPP-J20 mice and remained present in plaque-
bearing brains (Figure 2L); no A11 immunoreactivity was
observed in rTg9191 brain extracts from any age (Figures 2L,
S2A, and S2B; Liu et al., 2015). A11 and OC immunoreactivity
disappeared when extracts were immunodepleted of Ab using
a mixture of Ab antibodies prior to immunoblotting (Figures
Figure 3. Suppression of Transgenic APP
Selectively Lowers A11-Immunoreactive
Abo in TetO-APPSweInd Mice
(A) (Top) Protein aggregates detected by OC an-
tibodies in aqueous brain extracts prepared from
8.5-month-old TetO-APPSweInd mice harboring
both activator and responder transgenes (APP/
TTA) or only the activator transgene (TTA). DOX,
mice administered doxycycline to suppress APP
expression for the 5 weeks immediately preceding
sacrifice; Ctl, untreated mice; upper lane, brain
extracts; lower lane, brain extracts immunode-
pleted of Ab. (Bottom) a-tubulin served as the
loading control.
(B) Quantification of OC immunoreactivity. There is
no difference between levels of OC immunoreac-
tivity, normalized to a-tubulin levels, in extracts
from control (Ctl) and DOX-treated mice.
(C) (Top) Protein aggregates detected by A11 in
the extracts described in (A) are shown. Upper
lane, brain extracts; lower lane, brain extracts
immunodepleted of Ab. (Bottom) a-tubulin served
as the loading control.
(D) Quantification of A11 immunoreactivity.
Suppression of transgenic APP expression in
TetO-APPSweInd mice resulted in an 60%
reduction in the levels of A11-reactive oligomers.
n.s., not significant; #p < 0.05, two-way ANOVA
followed by Fisher’s post hoc analysis; error bars
represent SEM. See also Figure S7.S2C and S2D), demonstrating that the oligomers seen by A11
and OC in the brains of APP transgenic mice were indeed
composed of Ab. These results show that A11 and OC anti-
bodies recognize different structures generated in vivo, as there
exist brain-derived Ab assemblies that are A11-positive/OC-
negative (in young Tg2576 and hAPP-J20 mice) or OC-posi-
tive/A11-negative (in rTg9191 mice), extending the findings
that OC and A11 recognize mutually exclusive epitopes on syn-
thetic Abo generated in vitro (Kayed et al., 2007; Wu et al., 2010).
Reducing APP in Plaque-Bearing Mice Selectively
Lowers A11-Reactive Abo
Tg2576, hAPP-J20, TetO-APPSweInd, and rTg9191 mice express
human APP at levels that vary among lines and contain one or
more variants (Swedish in Tg2576, both Swedish and Indiana
in hAPP-J20 and TetO-APPSweInd, and both Swedish and
London in rTg9191). These alterations result in different levels
and amino acid compositions of Ab, which we hypothesize
contribute to the variability in the amount and types of Abo
generated, by analogy with in vitro studies. To determine
whether the amount of Ab expressed does indeed affect the
relative levels of A11- and OC-reactive Abo, we turned to
TetO-APPSweInd mice. Thesemice carry a regulatable APP trans-
gene, allowing us to manipulate levels of APP expression and,
hence, levels of Ab. When APP expression was suppressed by
90% for 5 weeks in plaque-bearing TetO-APPSweInd mice,
TBS-soluble A11-reactive species decreased 60%, but TBS-
soluble OC-reactive species remained stable (Figure 3). These
results support the hypothesis that, in the presence of amyloid
fibrils, the reaction kinetics favor the generation of OC-reactive
over A11-reactive Abo.CeType 2 Abo Are Concentrated around Dense-Core
Plaques and Occupy Only a Small Fraction of the Cortex
We went on to use OC antibodies to detect Abo in the brains of
two mouse models: rTg9191 and Tg2576. We found that brains
of both rTg9191 and Tg2576 mice showed areas of intense OC
immunoreactivity encircling Congo red-positive dense plaque
cores (Figure S3A). In contrast to dense-core plaques, we found
no OC reactivity in diffuse plaques lacking dense cores and pla-
que-associated cytopathology (Serrano-Pozo et al., 2011).
Since immunohistological methods are not optimally suited to
measure finely dispersedmolecules, it is possible that we did not
detect low concentrations of OC-immunoreactive Abo located
outside the immediate vicinity of dense-core plaques. We there-
fore performed biochemical analyses on microdissected brain
tissue fractions to more accurately define the spatial distribution
of OC-immunoreactive Abo and to discriminate between insol-
uble and soluble OC-immunoreactive assemblies.
Using laser microdissection, we isolated three tissue frac-
tions in rTg9191 mice: (1) dense plaque cores containing Ab
fibrils; (2) halos extending 50 mm from the edge of the plaque
cores; and (3) plaque-free zones, annuli extending 80–100 mm
from the outer edges of the halos (Figure 4A). We opted to
use autofluorescence rather than thioflavin S to identify candi-
date dense-core plaques, because thioflavin S artificially gener-
ated SDS-stable oligomers (Figure S3B). We performed control
studies to verify the identity of autofluorescent structures by
thioflavin S and Ab immunohistochemistry using 4G8 (Fig-
ure S3C). We then measured native Ab assemblies in each
tissue fraction in dot blots using OC antibodies, and we found
>99.9% of immunoreactivity confined to the cores and halos
(Figures 4B and 4C).ll Reports 11, 1760–1771, June 23, 2015 ª2015 The Authors 1763
Figure 4. Type 2 Abo Are Confined to
Dense-Core Plaques in rTg9191 Mice
(A) Photomicrographs show microdissected
fractions. White scale bars, 100 mm.
(B) (Top) Dot blot, probed with OC antibodies,
illustrates the topographical distribution of native
type 2 Abo. (Bottom) Above blot was stripped and
re-probed with anti-a-tubulin, showing that equal
amounts of protein were loaded for the halo and
plaque-free regions.
(C) Quantification of dot blots. OC-reactive
aggregates are confined to the dense-core and
halo regions.
(D) Immunoblotting under denaturing conditions
confirms that type 2 Abo are restricted to the
dense-core and halo regions. (Top) Western
blot shows full-length APP (fl-APP) in detergent-
soluble extracts of laser-microdissected fractions.
Fl-APP was immunoprecipitated with a polyclonal
antibody directed against a C-terminal epitope in
APP (anti-APPct) and detected using 6E10; blot
was stripped and re-probed with an antibody
directed against rabbit immunoglobulin (IgG),
showing that approximately equal amounts of
capture antibody were immunoprecipitated.
(Bottom) Western blot was probed with mono-
clonal antibody 6E10; blot was stripped and re-
probed with anti-a-tubulin.
(E) Quantification of western blots. Type 2 Abo and
monomers reside in the dense-core and halo
regions, while fl-APP is primarily found in halo and
plaque-free regions. *p < 0.01, **p < 0.001, ***p <
0.0001, one-way ANOVA followed by Fisher’s post
hoc analysis; error bars represent SEM. 1-mer, Ab
monomer; s/fl-APP, soluble and full-length amy-
loid precursor protein; Tg-, non-transgenic litter-
mates of rTg9191 mice; IgGH, immunoglobulin
heavy chain. See also Figures S3, S4, and S7.OC-immunoreactive Abo thus are spatially, as well as tempo-
rally, associated with amyloid fibrils in the brains of APP trans-
genic mice. Further, OC-immunoreactive Abo very probably
share the in-register parallel b sheet structure that is character-
istic of brain-derived amyloid fibrils (Lu et al., 2013). The spatial
and temporal patterns of appearance of OC-immunoreactive
oligomers strongly support the hypothesis that these oligomers
form via a process of secondary self-assembly dependent1764 Cell Reports 11, 1760–1771, June 23, 2015 ª2015 The Authorsupon pre-existing amyloid fibrils (see
Discussion and Figure S7). We here-
after refer to OC-positive oligomers that
exhibit spatial and temporal relationships
to amyloid fibrils as type 2 Abo. The laser
microdissection results indicated that
approximately all OC-immunoreactive
Abo in the brains of rTg9191 mice meet
the spatial criterion for type 2 oligomers.
We next asked what fraction of the
cortex is occupied by type 2 oligomers.
Based on stereological analyses of
thioflavin S-stained sections and the ge-
ometry of dense-core plaques (see theSupplemental Experimental Procedures), we estimated the vol-
ume of the cortex occupied by type 2 Abo in rTg9191 mice to
be 11.4%; therefore, >99.9% of the OC-immunoreactive Abo
in rTg9191 mice was confined to 11.4% of the cortex.
To measure other potential soluble Ab assemblies in rTg9191
brains, we solubilized the Ab assemblies from each tissue
fraction in detergents, fractionated them by SDS-PAGE (which
denatures the assemblies, as described below), and detected
Figure 5. Type 2 Abo and Ab*56 Have
Different Spatial Distributions in the Brains
of Tg2576 Mice
(A) (Top) Dot blot probed with OC antibodies
shows the topographical distribution of type 2
Abo. (Bottom) a-tubulin blot shows that equal
amounts of protein were loaded for the halo and
plaque-free regions.
(B) Quantification of dot blots. Type 2 Abo over-
whelmingly reside in the dense-core and halo
regions.
(C) (Top) Western blot shows fl-APP in detergent-
soluble extracts of laser-microdissected fractions;
blot was stripped and re-probed with anti-rabbit
IgG antibody, showing that approximately equal
amounts of capture antibody were immunopre-
cipitated. (Bottom) Western blot probed with 6E10
antibody shows the topographical distributions of
APP, Ab*56, and monomers (1-mer); a-tubulin blot
shows that equivalent amounts of protein were
loaded in the halo and plaque-free lanes.
(D) Quantification of western blots. Ab*56 and
fl-APP are primarily found in halo and plaque-
free regions. In contrast, Ab monomers over-
whelmingly reside in the dense-core and halo
regions. #p < 0.05, *p < 0.01, **p < 0.001,
***p < 0.0001, one-way ANOVA followed by
Fisher’s post hoc analysis; error bars represent
SEM. Tg-, non-transgenic littermates of Tg2576;
other abbreviations as in Figure 4. See also Fig-
ures S3, S4, and S7.the denatured Ab assemblies by immunoblotting with two
different anti-Ab antibodies (6E10, Figure 4D; 4G8, Figure S4A).
We found an array of Ab species in the cores and halos, but no Ab
assemblies in the plaque-free fraction. In addition, we found a
strong concordance between measurements of the percentage
of soluble Ab assemblies located in the cores and halos obtained
from dot blots with OC antibodies (>99.9%, Figure 4C) and mea-
surements obtained from western blots with the two anti-Ab an-
tibodies (R99.6%, Figures 4E and S4B), suggesting that all, or
nearly all, of the soluble Abo in rTg9191 mice is type 2 Abo.
In additional biochemical studies, we found that when extracts
of rTg9191 brains containing native type 2 Abo were fractionated
by size-exclusion chromatography and subsequently denatured
by SDS-PAGE, Ab species appeared in immunoblots as mono-
mers, dimers, and larger oligomers (Figure S4C). Dimers were
the most abundant Ab oligomeric species in the immunoblots
and eluted in two distinct sets of fractions; one set of fractions
corresponded to the molecular masses of globular proteins
ranging from500 to2,000 kDa, while the other set of fractionsCell Reports 11, 1760–177corresponded to 60 to 200 kDa pro-
teins. We inferred from these results that
the dimers in the immunoblots of dena-
tured rTg9191 brain extracts represent
disassembled high-molecular-mass type
2 Abo, but we cannot exclude the exis-
tence of free non-globular dimers with
larger radii of hydration than would be ex-
pected for a globular protein with a mo-lecular mass of 9 kDa, the theoretical molecular mass of
dimers.
The Type 1 AbOligomer Ab*56 Is Distributed throughout
the Cortex
The A11-immunoreactive oligomer Ab*56 appears months
before the emergence of the first detectable dense-core plaques
in Tg2576 (Kawarabayashi et al., 2001; Lesne´ et al., 2006) and
hAPP-J20 (Cheng et al., 2007; Wright et al., 2013) mice. We
used Tg2576 mice, in which Ab*56 was originally described
(Lesne´ et al., 2006), to compare the spatial distribution of
Ab*56 to that of type 2 Abo. We analyzed microdissected tissue
fractions by dot blotting and western blotting (Figures 5A, 5C,
and S4D). In quantitative analyses, we found a striking diver-
gence in the distribution of OC-immunoreactive Abo and
Ab*56: 99.5% of OC-immunoreactive Abo was concentrated
within plaque cores and halos (Figure 5B), whereas most of the
Ab*56 (R98.7%) was distributed outside the core, in the halo
and plaque-free zone (Figures 5D and S4E). We estimated that1, June 23, 2015 ª2015 The Authors 1765
Table 1. TheRelative Levels andSpatial Occupancy of Type 1 and
Type 2 Abo in Aged Tg2576 Mice
Type of Abo




Type 2 14,500 ± 1,500a 13.9b
Ab*56 (type 1) 57 ± 2c 98.4b
Total Ab 15,200 ± 7,000d NA
See also Figures S5 and S7. NA, not applicable.
aSee Figure S5A.
bSee Supplemental Experimental Procedures for calculations.
cSee Figure S5B, assuming stoichiometry of 6E10:Ab*56 is 12:1.
dSee Figure S5C for calculations.type 2 Abo and Ab*56 occupy 13.9% and 98.4%, respectively, of
the volume of the cortex we sampled in aged Tg2576 mice (see
the Supplemental Experimental Procedures).
Thus, in contrast to type 2 Abo, Ab*56 differs from amyloid
fibrils in its temporal expression; spatial distribution; and qua-
ternary structure, as inferred from its immunoreactivity with
conformation-selective antibodies. We hereafter refer to A11-
positive oligomers that appear independently of amyloid fibrils
as type 1 Abo.
Type 2 Abo Levels Greatly Exceed Those of the Type 1
Oligomer Ab*56 in Aqueous Brain Extracts from Tg2576
Mice
To determine the relative abundance of type 2 Abo and Ab*56,
we estimated their masses in aqueous brain extracts from
21-month-old Tg2576 mice. To ascertain the Ab content of
type 2 Abo, we compared OC immunoreactivity of extracts to
that of synthetically produced in-register parallel b sheet Ab
fibrils containing known quantities of Ab (measured by ELISA
using 6E10 antibodies, following denaturation with hexa-fluoro-
isopropanol [HFIP]). This method assumes that the relationship
between OC immunoreactivity and Ab content is the same
for the synthetic fibrils and brain-derived type 2 Abo. Using this
method, type 2 oligomers were found to contain 14,500 ±
1,500 ng Ab per gram of brain tissue. Levels of Ab*56 were
assessed by comparing the density of the 56-kDa band to known
quantities of synthetic Ab monomers on western blots probed
with 6E10. This method assumes that the affinity of the 6E10
antibody was the same for the Ab peptides within Ab*56 as for
the synthetic Ab in blots subjected to antigen retrieval prior to
incubation with 6E10. Our estimate of the amount of Ab*56 de-
pended on the stoichiometry of antibody binding to the synthetic
standards and to Ab*56. We assumed a stoichiometry of antibo-
dy:Ab monomer of 1:1. Each molecule of Ab*56, a putative Ab
dodecamer, could bind between 1 and 12 antibody molecules.
Under the assumption that one molecule of Ab*56 binds 12 anti-
bodies (i.e., a 1:1 antibody:monomeric sub-unit ratio), we found
that Ab*56 contains 57 ± 2 ng Ab per gram of brain tissue. How-
ever, this value could be as much as 12 times higher, if only one
antibody binds to each molecule of Ab*56. Finally, the total mass
of Ab (Abx38, Abx40, and Abx42) in the extracts was measured
by ELISA using 6E10 antibodies, following denaturation with
formic acid. We found that the total Ab in aqueous extracts1766 Cell Reports 11, 1760–1771, June 23, 2015 ª2015 The Authorsfrom aged Tg2576 mice is comprised of 0.4%–4.8% Ab*56
and 95% type 2 Abo (Table 1; Figure S5).
Mice Producing Only Type 2 Abo Are Cognitively Intact
Multiple studies have shown a correlation between the type
1 Abo Ab*56 andmemory dysfunction in transgenicmice (Billings
et al., 2007; Cheng et al., 2007; Lesne´ et al., 2006). The rTg9191
mice provided the opportunity to test the effects of type 2 Abo on
cognition, as rTg9191 mice produce type 2 Abo exclusively. We
studied cognitive function in rTg9191 mice that were aged until
21–24 months, when the relative quantity of type 2 Abo in the
brain, as assessed in dot blots usingOC antibodies, was compa-
rable to that in AD patients (Figures 6A and 6B). In a cohort of
mice tested at 23 months, we found no significant transgene-
associated effects on cognitive performance in the fixed consec-
utive number (FCN) task, an operant behavioral task sensitive to
lesions of the prefrontal cortex (van Haaren et al., 1988; Fig-
ure 6C). Similarly, we found no significant impairment of spatial
memory in any of three other cohorts of mice (young [4 months],
middle-aged [12 months], and old [21 months]), evaluated using
a water maze test of spatial referencememory that is sensitive to
hippocampal lesions (Morris, 2007; Figure 6D). When the cohort
of old mice was re-tested at 24 months, when levels of type
2 Abo were significantly higher than in 21-month-old mice, there
was still no decrement in performance (Table S1). Furthermore,
there were no significant differences in performances between
the old cohort (21 months old) and the other two cohorts (Fig-
ure 6D; Table S1). The slight increase in the proximity index (Ta-
ble S1) and decrease in target-quadrant occupancy in the old
mice appeared to be related to aging, since the same decrease
can be seen in old, non-transgenic littermates (Figure 6D). Based
on OC immunoreactivity in dot blots, the levels of type 2 Abo in
24-month-old mice were 25- and 2.1-fold greater (calculated
after subtracting background immunoreactivity observed in
non-transgenic mice) than those in 4- and 12-month-old mice,
respectively (Figure 6B). In summary, within the statistical limits
of our measurements, there were no differences in cognitive
function between mice with type 2 Abo (at levels comparable
to those in humans with AD), non-transgenic mice, and young
rTg9191 mice with few or no such oligomers.
Type 2Abo Impair CognitionwhenDispersed andTested
in Rats
The absence of any impact on cognitive function of type 2 Abo
produced in situ suggests that type 2 Abo sequestered within
dense-core plaques do not interfere with global network func-
tion, or that compensatory neural reorganization effectively pre-
serves brain function when the oligomers occupy <15% of the
cortex. It is possible that the background strain (129FVBF1) of
rTg9191 is not permissive for the disruptive effects of Ab on
cognition, but this is unlikely because Tg2576 mice in the same
background strain showed spatial memory deficits (Kotilinek
et al., 2008). We also considered the possibility that the type 2
Abo produced by rTg9191 mice lacked neurotoxicity. To test
this hypothesis, we prepared aqueous protein extracts contain-
ing type 2 Abo from the brains of 26-month-old rTg9191 mice,
and we injected the extracts into the lateral cerebral ventricles
of rats previously trained in a delayed non-matching-to-place
Figure 6. Type 2 Abo Do Not Disrupt Cogni-
tion when Located In Situ in rTg9191 Brains,
but Do Impair Cognition when Dispersed
(A–D) rTg9191 mice producing levels of type 2 Abo
comparable to those of AD patients have intact
cognition. (A) (Top) Dot blot shows the relative
levels of soluble OC-reactive aggregates in the
brains of rTg9191 mice, non-transgenic littermates
(nTg) and AD patients. Ages of mice are shown
above the blot. Upper lane, water-soluble brain
extracts and synthetic aggregates; lower lane,
samples immunodepleted of Ab; syn, synthetic
soluble Ab aggregates with in-register parallel
b sheets. (Bottom) a-tubulin served as the loading
control for both the untreated (upper lane) and
Ab-immunodepleted extracts (lower lane).
(B)Quantificationofdotblots. LevelsofOC-reactive
aggregates in the brains of rTg9191 mice increase
with age (#p < 0.05, *p < 0.01, ***p < 0.0001, one-
wayANOVAfollowedbyFisher’sposthocanalysis).
(C) Cognitive performance in 23-month-old APP-
positive (rTg9191) and -negative (neg) rTg9191
mice do not differ in the signaled and unsignaled
components of the FCN-4 test. The probability of a
given trial producing an error in the signaled
component is significantly lower than in the un-
signaled component, indicating intact motor and
visual function (***p < 0.0001, paired t test).
(D) Spatial reference memory in rTg9191mice does
not differ significantly from that of APP-neg litter-
mates. Young (4months),middle-aged (12months),
and old (21 months) mice were tested in the water
maze; mean percentage time in each quadrant
(target, red; left of target, yellow; right of target,
orange; and opposite the target, gray) is shown.
Significant search biases favoring the target quad-
rant were found in both rTg9191mice and APP-neg
littermates at all three ages. #p < 0.05, *p < 0.01,
**p < 0.001, ***p < 0.0001, percentage time spent in
the target compared to that in each of the other
three quadrants, repeated-measures ANOVA (RM-
ANOVA) followed by Fisher’s post hoc analysis.
Numerals in (C) and (D) represent the number of
mice tested.
(E)Water-soluble brain extracts of rTg9191mice containing type 2 Abo disrupt cognitionwhen exogenously administered to rats. Rats (n = 18) previously trainedon a
delayed non-matching–to-place task were injected intracerebroventricularly with brain extracts of rTg9191 mice containing type 2 Abo or with extracts
immunodepleted of Ab (vehicle). Type 2 Abo, but not vehicle, injections impaired performance on this task (*p < 0.01, RMANOVA compared to baseline performance
[mean of three contiguous sessions]). (Inset) Dot blot showsOC immunoreactivity in type 2 Abo-containing (type 2) and immunodepleted (vehicle) injectates. In (B–E),
error bars represent SEM. See also Figure S6 and Table S1.task, a test of short-term working memory (Paule et al., 1998).
Each rat sequentially received brain extracts containing 0%
(Ab immunodepletion), 0.1% (low dose), or 1% (high dose)
of the total amount of type 2 Abo in a 26-month-old rTg9191
mouse, and was tested 2 hr after the injections. Compared to
baseline performance, memory was significantly impaired
when rats were injected with the high dose of Ab-containing
extracts, but not when rats received the low dose or extracts
from which Ab was depleted (Figures 6E and S6). These results
indicate that normal cognition in rTg9191 mice is probably not
due to the lack of neurotoxicity of type 2 Abo, since extracts con-
taining minute quantities of dispersed type 2 Abo disrupted
cognition. These findings support the conclusion that spatialCelocalization is a more significant determinant of the neurological
effects of Abo than overall abundance.
DISCUSSION
The data in this paper indicate that brain-derived Abo can be
categorized based on distinct temporal, spatial, and structural
relationships to fibrils. Type 2 Abo are observed only after
dense-core plaque formation, are highly concentrated around
dense-core plaques, and are recognized by OC antibodies,
which we here show selectively bind to structures containing
in-register parallel b sheets. The in-register parallel b sheet
conformation is characteristic of all known naturally occurring
Ab fibrils (for review, see Glabe, 2009 and Tycko, 2011), so itll Reports 11, 1760–1771, June 23, 2015 ª2015 The Authors 1767
appears that type 2 Abo and Ab fibrils share a common quater-
nary structure. By contrast, type 1 Abo are present both prior
to and following the appearance of dense-core plaques, are
dispersed in brain tissue, and are recognized by A11 antibodies.
Importantly, these two classes of Abo are differentially associ-
ated with impaired cognition: the type 1 Abo Ab*56 is associated
with memory dysfunction in APP transgenic mice (Billings et al.,
2007; Cheng et al., 2007; Lesne´ et al., 2006, 2008), while mice
with levels of type 2 oligomers similar to those of AD patients
have intact cognition. These results are summarized in Table
S2. Taken together, these findings refine our understanding of
how Abo are organized and impact global neural network func-
tion in the brain.
The results of recently reported behavioral studies in TetO-
APPSweInd mice are consistent with our conclusion that type
2 Abo are less harmful to neurological function than type 1 Abo
(Fowler et al., 2014). Using TetO-APPSweInd mice of the identical
age and strain background, exposed to the same dose of doxy-
cycline for the same amount of time as the mice used here,
Fowler et al. (2014) showed that 90% suppression of APP
expression led to cognitive improvement, assayed with multiple
behavioral tests. Cognitive improvement in these mice was
accompanied by significant reductions in the level of A11-immu-
noreactive species generally, and in the level of Ab*56 particu-
larly, with no changes in amyloid plaque burden. In the current
study, we have confirmed the findings of Fowler et al. (2014),
showing that suppression of APP leads to reductions in A11-im-
munoreacitve species, and we have extended these findings to
show that levels of OC-immunoreactive Abo are unchanged.
To summarize, an experimental manipulation that reduces levels
of A11-reactive Abo, while preserving levels of OC-reactive Abo,
leads to cognitive improvement in TetO-APPSweInd mice.
We hypothesize that the differences in the spatiotemporal dis-
tributions of type 1 and type 2 Abo result from distinct modes of
biogenesis. Abo have been shown in vitro to form via one of two
processes: (1) primary self-assembly occurring independently of
amyloid fibrils, or (2) secondary self-assembly requiring pre-ex-
isting fibrils that catalyze the self-assembly of monomers (Cohen
et al., 2013; Figure S7). If these processes also occur in vivo, Abo
formed via secondary self-assembly should be seen only in
brains containing amyloid fibrils and should be at highest con-
centration in the immediate vicinity of foci of Ab fibrils (i.e.,
dense-core plaques). We propose that type 2 Abo are generated
by a secondary self-assembly process, because they appear
only after dense-core plaques are present and they are highly
concentrated around these plaques. Conversely, Abo that form
via primary self-assembly may be present prior to plaque forma-
tion and need not be concentrated around plaques—character-
istics of type 1 Abo, as defined here.
The two-pathway model of the self-assembly of Ab (Figure S7)
can explain the quantitative differences between type 1 and type
2 Abo reported here. In vitro studies have shown that, in the pres-
ence of amyloid fibrils, reaction kinetics favor the generation of
oligomers via a secondary self-assembly process (Cohen
et al., 2013). After amyloid fibrils form in vitro, Ab monomers
are consumed by the elongation of fibrils and the secondary
self-assembly reaction; if the consumption of monomers by
these processes exceeds the production of Ab monomers1768 Cell Reports 11, 1760–1771, June 23, 2015 ª2015 The Authorsneeded to form Abo via primary self-assembly, then Abo formed
by primary self-assembly will decline or disappear. This model
predicts that type 2 Abo should predominate in plaque-bearing
brains; indeed, type 2 Abo are the most abundant Abo in aged
Tg2576 mice, comprising 95% of the Ab species in aqueous
brain extracts from Tg2576 mice (with plaque loads slightly
higher than those found in AD). The model also anticipates our
result in vivo in TetO-APPSweInd mice: when we reduced the
pool of monomers by lowering APP expression, levels of type
1 Abo fell but levels of type 2 Abo remained unchanged. Finally,
the presence of type 1 Abo in Tg2576 mice and absence in
rTg9191 mice also are consistent with this model. Tg2576 mice
express more total Ab than rTg9191 mice, but relatively less
fibrillogenic Ab42, because Tg2576 lack the London mutation;
therefore, more monomers are available to form type 1 Abo in
Tg2576 than in rTg9191 mice.
Surprisingly, the prolific type 2 Abo were not dispersed
throughout brain tissue, but were instead encapsulated around
dense-core plaques that in total occupied <15% of the cortex.
Within thismicroenvironment, type 2Abo very likely cause neuro-
degenerative changes such as dystrophic neurites. It was shown
previously that anti-Ab immunotherapy reverses plaque-associ-
ated neuritic abnormalities without affecting plaque burden
(Rozkalne et al., 2009), strongly suggesting that soluble Abo
cause cytopathology. Our rTg9191 mice, which generate only
type 2 Abo, exhibited plaque-associated cytopathology (Liu
et al., 2015), yet remained cognitively normal. Thus, the encapsu-
lation of type 2 Abo in cyst-like dense-core plaques appears to
neutralize their potential to disrupt neurological function. These
results indicate that the spatial localization of Abo is critically
important, certainlymore important than their overall abundance.
To evaluate the relevance of our findings to AD, we estimated
the volume of human cortex occupied by type 2 Abo in AD, using
two different methods. One method depended on immunohisto-
logical data of tissue stained with the Abo-specific antibody
NAB-61 (Lee et al., 2006), which we inferred selectively recog-
nizes type 2 Abo and amyloid fibrils from its almost exclusive
staining of neuritic plaques (dense-core plaques associated
with neuritic abnormalities [Serrano-Pozo et al., 2011]). The
average volume of AD cortex occupied by Ab assemblies de-
tected using NAB-61 was 5% (Perez-Nievas et al., 2013). The
other method relied on neuritic plaque densities. We estimated
that the upper limit of the volume of cortex occupied by neuritic
plaques in AD brain is 10% (see the Supplemental Experi-
mental Procedures). Both estimates were smaller than those in
the Tg2576 and rTg9191 mouse model systems studied here,
suggesting that, in humans, type 2 Abo influence a relatively
small volume of cortex and, as in themice, would participate little
if at all in disrupting cognition or inducing widespread neurode-
generation. However, we cannot exclude the possibility that
type 2 Abo might disrupt intrinsic connectivity networks in AD if
higher-than-average concentrations of neuritic plaques accu-
mulate in critical nodes. Nor can we conclude with certainty
that type 1 Abo levels are equivalent across all brain regions;
for example, within a given region, local rates of Ab production
may be affected by neural activity (Cirrito et al., 2005; Kamenetz
et al., 2003), which might alter the kinetics of self-assembly. A
better understanding of the roles of type 1 and type 2 Abo in
ADmight be gained by comparing their respective levels in brain
regions that are differentially vulnerable to neurodegenerative
and functional abnormalities.
Although the biological factors involved in maintaining the
sequestration of type 2 Abo in dense-core plaques are not well
understood, neuroinflammation seems to be important. While
type 2 Abo are smaller and, therefore, more diffusible than amy-
loid fibrils, their diffusion range may be circumscribed by micro-
glial cells that may seal them inside amyloid plaques (Bolmont
et al., 2008), thus potentially limiting their influence on brain func-
tion. It is possible that the compartmentalization eventually
breaks down in symptomatic AD patients, allowing type 2 Abo
to leak out and damage a broader population of neurons. If
type 2 Abo in AD are as neurotoxic as those in rTg9191 mice,
our results indicate that small breaches allowing only 1% to
pass through the putative barrier might be sufficient to disrupt
global network function. Actual quantification is needed to test
the hypothesis directly, but the poor correlation among neuritic
plaques, b-amyloidosis, and cognition in humans (Katzman
et al., 1988; Terry et al., 1991) argues against this possibility.
The uncertainty about which Abo contribute to the patho-
genesis of AD is a major impediment to progress on disease
prevention, treatment, and diagnosis. Apparently conflicting
results obtained in clinical trials of anti-amyloid therapies
highlight the need for a more complete understanding of the
types and toxicity of Ab assemblies that are seen during the
progression of AD. Passive immunization with two monoclonal
antibodies that recognize Ab fibrils, bapineuzumab and gante-
nerumab, reduced amyloid burdens but failed to provide cogni-
tive or functional benefits (Alzforum, 2015a, 2015b; Ostrowitzki
et al., 2012; Rinne et al., 2010). However, preliminary reports
that a third antibody, aducanumab, practically eliminates pla-
ques and slows cognitive and functional declines in patients
with prodromal or mild AD have generated tremendous excite-
ment in the field (Strobel, 2015). Aducanumab reportedly is
highly selective for Abo over Ab monomers, but further details
of the conformational selectivity of the antibody have not
been made public. Taken together with the findings in mice re-
ported here, the results of the clinical trials raise several ques-
tions. How did the stage at which therapy was administered,
the degree of target engagement, and/or the precise identities
of Ab species targeted contribute to the differences in the
outcomes of the clinical trials? Does aducanumab discriminate
between type 1 and type 2 Abo, as defined here, or does it
recognize an epitope common to both types of Abo? Does
the microlocalization of different structural classes of Abo in
human brain parallel that seen in the brains of APP transgenic
mice, reported here, and does this spatial distribution change
during the progression of AD from the prodromal phase to de-
mentia? Are there regions of the human brain where type 2 Abo
reach a high enough concentration to disrupt network function
(the critical nodes mentioned above)?
In summary, the findings reported here suggest that, while
most of the soluble Ab in brains bearing dense-core plaques
(e.g., AD brains) are type 2 Abo, the bulk of these oligomers
are rendered functionally innocuous by their effective contain-
ment within plaques. Type 1 Abo may be more directly patho-
genic in many brain regions because they are more finelyCedispersed than type 2 Abo. We hope that our findings will
open up new directions of research, particularly in understand-
ing and developing therapies that target the rarer type 1 Abo. A
better understanding of how type 1 and type 2 Abo impact the
pathogenesis of AD may result from the synthesis of future bio-
physical and biological studies.
EXPERIMENTAL PROCEDURES
Animals
The rTg9191 mice were generated using a binary system of responder and
activator transgenes (Paulson et al., 2008). Tg2576 mice (Hsiao et al., 1996)
in a B6SJLF1 background (Westerman et al., 2002) and 4-month-old
hAPPJ20 mice in a C57Bl6 background were from K.H.A.’s colony at the
University of Minnesota. TetO-APPSweInd mice in a B6FVB F1 background
were from J.L.J.’s laboratory at Baylor College of Medicine. Brains from
12-month-old hAPP-J20 were a gift from Dr. Lennart Mucke of the Univer-
sity of California, San Francisco. All experiments involving mice and rats
were conducted in full accordance with the Association for Assessment
and Accreditation of Laboratory Animal Care and the Institutional Animal
Care and Use Committee guidelines at the University of Minnesota,
Minneapolis Veterans Administration Medical Center, or Baylor College of
Medicine.
Human Brain Tissue
De-identified samples of inferior temporal gyrus (Brodmann Area 20) from
individuals with a clinical diagnosis of AD were obtained from the Religious
Orders Study (Rush Alzheimer’s Disease Center). The Religious Orders Study
is approved by the Institutional Review Board of Rush University Medical
Center.
Sample Preparation for Parallel and Anti-parallel Fibrils and
Synthetic Abo
Details of preparation procedures are provided in the Supplemental Experi-
mental Procedures.
Protein Extraction and Immunoblotting
To extract native Ab aggregates, water-soluble extracts were prepared based
on a protocol previously described (Shankar et al., 2008). Briefly, tissue spec-
imens were weighed and transferred to 4 vol ice-cold buffer (25 mM Tris-HCl
[pH 7.4], 140mMNaCl, 3mMKCl, 0.1mMPMSF, 0.2mM1,10-phenanthroline
monohydrate, protease inhibitor cocktail [Sigma-Aldrich], and phosphatase
inhibitor cocktails [Sigma-Aldrich]) and homogenized using a Dounce homog-
enizer. The resulting materials were centrifuged for 90 min (16,100 3 g, 4C);
the supernatant was depleted of endogenous immunoglobulins and stored
at 20C until further use.
Details of the dot blotting method are provided in the Supplemental Exper-
imental Procedures. Briefly, 0.5 mg protein from brain extracts or 0.02–2 ng
synthetic Ab fibrils (Qiang et al., 2012) was spotted onto nitrocellulose
membranes, which were then probed with either OC (Millipore, AB2286,
1:50,000) or A11 (Invitrogen, AHB0052, 1:1,000) antibodies.
Detergent-soluble Ab species were extracted and western blotting was per-
formed using the method of Liu et al. (2011).
Microdissection
Details of microdissection are provided in the Supplemental Experimental Pro-
cedures. Native and detergent-soluble proteins were extracted as described
above; to compare protein levels in the microdissected fractions, extracts
from equal volumes of tissue were used in dot blots and western blots. For
negative controls, protein extracts from age-matched, nontransgenic litter-
mates were loaded such that the total protein content equaled that of the
plaque-free regions used for each blot.
Behavioral Tests
Details of the behavioral tests are provided in the Supplemental Experimental
Procedures.ll Reports 11, 1760–1771, June 23, 2015 ª2015 The Authors 1769
FCN Task
Forty-one (19 rTg9191, 22 neg) mice completed training under this assay.Mice
were 20.5months old at the start of training. After training, micewere run under
the FCN-4 5 days/week for 30 daily sessions.
Water Maze
Spatial reference memory was measured in rTg9191 mice using a modified
version of a water maze tailored tomore rapid learning in the 129S6/FVB back-
ground strain and more sensitive to subtle deficits (Westerman et al., 2002).
The rTg9191 mice (female and male) were tested cross-sectionally at 4 and
12 months of age, and longitudinally from 21 to 24 months. The spatial cues
and hidden platform location were changed for the mice tested longitudinally
at 24 months of age. Illness and spontaneous deaths were observed at
the 21–24 month time point (4/60 neg and 6/40 rTg9191 mice; chi square,
p = 0.15). Mice requiring euthanasia were not included in the analysis. The
power of our study was sufficient to have an 80% chance of detecting an
eight-point drop in mean percentage target quadrant occupancy at a confi-
dence level of 0.05.
Delayed Non-Matching-to-Place Task
Twenty male Sprague-Dawley rats previously trained on a delayed
non-matching-to-place task were injected intracerebroventricularly with
brain extracts through chronically implanted guide cannulae (Reed et al.,
2011). Each rat received 10 ml brain extract, prepared using the protocol
for native aggregates described above; control extracts were prepared
by two rounds of immunodepletion with monoclonal antibody 4G8.
Animals were tested 2 hr post-injection. Each animal received injections
of both fibril-dependent Abo-containing and control extracts, on different
days.
The task yields an accuracy-by-delay relationship, with high accuracy
(percentage of correct responses) at the short delays and near random
performance (50% correct) at the longest delays. This relationship is
shifted leftward (working memory deficit) by compounds or conditions that
adversely affect cognition. Performance on the day of injection was
compared to baseline performance, defined as the mean of the scores at
each delay (percentage of correct choices) for 3 days contiguous to the
day of injection. Two animals that lost their cannulae were excluded from
the analysis.
Histology and Immunohistochemistry
Details of histological procedures are provided in the Supplemental Experi-
mental Procedures.
Statistics
Statistics were performed using StatView Version 5.0.1 (SAS Institute). Data
are expressed as mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.05.021.
AUTHOR CONTRIBUTIONS
P.L., K.R.Z., and K.H.A. conceived the project. P.L. planned and performed the
biochemistry experiments, including characterization of the rTg9191 mice and
laser microdissection, and analyzed the results. M.N.R., L.A.K., P.L., and
J.P.C. planned, performed, and analyzed the behavioral experiments.
M.K.O.G. performed biochemistry experiments, including dot blots and size-
exclusion chromatography. S.L.S. performed biochemistry experiments,
including dot blots. P.L. and C.L.F. planned, performed, and analyzed the
immunohistochemistry experiments. J.H.R. performed stereology-based
quantification of amyloid load in Tg2576 mice. W.Q. prepared synthetic amy-
loid fibrils and characterized them by electron microscopy. A.C.A.C. treated
and prepared tissue from TetO-APPSweInd mice. J.L.J. supplied tissue from
TetO-APPSweInd mice and contributed to the interpretation of results. P.L.,
C.M.W., K.R.Z., and K.H.A. wrote the paper.1770 Cell Reports 11, 1760–1771, June 23, 2015 ª2015 The AuthorsACKNOWLEDGMENTS
The authors thank Dr. David Bennett, Rush University Medical Center, for
providing human brain specimens; Dr. Sylvain Lesne´ and Mathew Sherman
for providing aqueous extracts of human brains; and Dr. Robert Tycko for valu-
able advice. This work was supported by the National Institute for Neurological
Diseases and Stroke (NS33249) and a gift from B. Grossman (K.H.A.), a grant
from the Robert A. and Renee E. Belfer Family Foundation (J.L.J.), and the NIH
intramural research program (W.Q.).
Received: March 31, 2015
Revised: May 4, 2015
Accepted: May 10, 2015
Published: June 4, 2015
REFERENCES
Alzforum (2015a). Bapineuzumab. http://www.alzforum.org/therapeutics/
bapineuzumab.
Alzforum (2015b). Gantenerumab. http://www.alzforum.org/therapeutics/
gantenerumab.
Benilova, I., Karran, E., and De Strooper, B. (2012). The toxic Ab oligomer and
Alzheimer’sdisease: anemperor in needof clothes.Nat.Neurosci.15, 349–357.
Billings, L.M., Green, K.N., McGaugh, J.L., and LaFerla, F.M. (2007). Learning
decreases A beta*56 and tau pathology and ameliorates behavioral decline in
3xTg-AD mice. J. Neurosci. 27, 751–761.
Bolmont, T., Haiss, F., Eicke, D., Radde, R., Mathis, C.A., Klunk, W.E.,
Kohsaka, S., Jucker, M., and Calhoun, M.E. (2008). Dynamics of the micro-
glial/amyloid interaction indicate a role in plaque maintenance. J. Neurosci.
28, 4283–4292.
Cheng, I.H., Scearce-Levie, K., Legleiter, J., Palop, J.J., Gerstein, H., Bien-Ly,
N., Puoliva¨li, J., Lesne´, S., Ashe, K.H., Muchowski, P.J., and Mucke, L. (2007).
Accelerating amyloid-beta fibrillization reduces oligomer levels and functional
deficits in Alzheimer diseasemousemodels. J. Biol. Chem. 282, 23818–23828.
Cirrito, J.R., Yamada, K.A., Finn, M.B., Sloviter, R.S., Bales, K.R., May, P.C.,
Schoepp, D.D., Paul, S.M., Mennerick, S., and Holtzman, D.M. (2005). Synap-
tic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48,
913–922.
Cohen, S.I., Linse, S., Luheshi, L.M., Hellstrand, E., White, D.A., Rajah, L., Ot-
zen, D.E., Vendruscolo, M., Dobson, C.M., and Knowles, T.P. (2013). Prolifer-
ation of amyloid-b42 aggregates occurs through a secondary nucleation
mechanism. Proc. Natl. Acad. Sci. USA 110, 9758–9763.
Fowler, S.W., Chiang, A.C., Savjani, R.R., Larson, M.E., Sherman, M.A.,
Schuler, D.R., Cirrito, J.R., Lesne´, S.E., and Jankowsky, J.L. (2014). Genetic
modulation of soluble Ab rescues cognitive and synaptic impairment in a
mouse model of Alzheimer’s disease. J. Neurosci. 34, 7871–7885.
Glabe, C.G. (2008). Structural classification of toxic amyloid oligomers. J. Biol.
Chem. 283, 29639–29643.
Glabe, C.G. (2009). Amyloid oligomer structures and toxicity. Open Biol. J. 2,
222–227.
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S.,
Yang, F., and Cole, G. (1996). Correlative memory deficits, Abeta elevation,
and amyloid plaques in transgenic mice. Science 274, 99–102.
Jankowsky, J.L., Slunt, H.H., Gonzales, V., Savonenko, A.V., Wen, J.C., Jen-
kins, N.A., Copeland, N.G., Younkin, L.H., Lester, H.A., Younkin, S.G., and
Borchelt, D.R. (2005). Persistent amyloidosis following suppression of Abeta
production in a transgenic model of Alzheimer disease. PLoS Med. 2, e355.
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T.,
Sisodia, S., and Malinow, R. (2003). APP processing and synaptic function.
Neuron 37, 925–937.
Katzman, R., Terry, R., DeTeresa, R., Brown, T., Davies, P., Fuld, P., Renbing,
X., and Peck, A. (1988). Clinical, pathological, and neurochemical changes in
dementia: a subgroup with preservedmental status and numerous neocortical
plaques. Ann. Neurol. 23, 138–144.
Kawarabayashi, T., Younkin, L.H., Saido, T.C., Shoji, M., Ashe, K.H., and
Younkin, S.G. (2001). Age-dependent changes in brain, CSF, and plasma
amyloid (b) protein in the Tg2576 transgenic mouse model of Alzheimer’s
disease. J. Neurosci. 21, 372–381.
Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman,
C.W., and Glabe, C.G. (2003). Common structure of soluble amyloid oligomers
implies common mechanism of pathogenesis. Science 300, 486–489.
Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C.W., Necula, M., Margol,
L., Wu, J., Breydo, L., Thompson, J.L., et al. (2007). Fibril specific, conforma-
tion dependent antibodies recognize a generic epitope common to amyloid
fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neuro-
degener. 2, 18.
Kotilinek, L.A., Westerman, M.A., Wang, Q., Panizzon, K., Lim, G.P., Simonyi,
A., Lesne, S., Falinska, A., Younkin, L.H., Younkin, S.G., et al. (2008).
Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression
of memory and synaptic plasticity. Brain 131, 651–664.
Laganowsky, A., Liu, C., Sawaya, M.R., Whitelegge, J.P., Park, J., Zhao, M.,
Pensalfini, A., Soriaga, A.B., Landau, M., Teng, P.K., et al. (2012). Atomic
view of a toxic amyloid small oligomer. Science 335, 1228–1231.
Lasagna-Reeves, C.A., Glabe, C.G., and Kayed, R. (2011). Amyloid-b annular
protofibrils evade fibrillar fate in Alzheimer disease brain. J. Biol. Chem. 286,
22122–22130.
Lee, E.B., Leng, L.Z., Zhang, B., Kwong, L., Trojanowski, J.Q., Abel, T., and
Lee, V.M. (2006). Targeting amyloid-beta peptide (Abeta) oligomers by passive
immunization with a conformation-selective monoclonal antibody improves
learning and memory in Abeta precursor protein (APP) transgenic mice.
J. Biol. Chem. 281, 4292–4299.
Lesne´, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher,
M., and Ashe, K.H. (2006). A specific amyloid-beta protein assembly in the
brain impairs memory. Nature 440, 352–357.
Lesne´, S., Kotilinek, L., and Ashe, K.H. (2008). Plaque-bearing mice with
reduced levels of oligomeric amyloid-beta assemblies have intact memory
function. Neuroscience 151, 745–749.
Lesne´, S.E., Sherman, M.A., Grant, M., Kuskowski, M., Schneider, J.A.,
Bennett, D.A., and Ashe, K.H. (2013). Brain amyloid-b oligomers in ageing
and Alzheimer’s disease. Brain 136, 1383–1398.
Liu, P., Kemper, L.J., Wang, J., Zahs, K.R., Ashe, K.H., and Pasinetti, G.M.
(2011). Grape seed polyphenolic extract specifically decreases ab*56 in the
brains of Tg2576 mice. J. Alzheimers Dis. 26, 657–666.
Liu, C., Zhao, M., Jiang, L., Cheng, P.N., Park, J., Sawaya, M.R., Pensalfini, A.,
Gou, D., Berk, A.J., Glabe, C.G., et al. (2012). Out-of-register b-sheets suggest
a pathway to toxic amyloid aggregates. Proc. Natl. Acad. Sci. USA 109,
20913–20918.
Liu, P., Paulson, J.B., Forster, C.L., Shapiro, S.L., Ashe, K.H., and Zahs, K.R.
(2015). Characterization of a novel mouse model of Alzheimer’s disease-
amyloid pathology and unique b-amyloid oligomer profile. PLoS ONE 10,
e0126317.
Lu, J.X., Qiang,W., Yau,W.M., Schwieters, C.D., Meredith, S.C., and Tycko, R.
(2013). Molecular structure of b-amyloid fibrils in Alzheimer’s disease brain
tissue. Cell 154, 1257–1268.
Morris, R. (2007). Theories of hippocampal function. In The Hippocampus
Book, P. Andersen, R.Morris, D. Amaral, T. Bliss, and J. O’Keefe, eds. (Oxford:
Oxford University Press), pp. 581–694.
Noguchi, A., Matsumura, S., Dezawa, M., Tada, M., Yanazawa, M., Ito, A.,
Akioka, M., Kikuchi, S., Sato, M., Ideno, S., et al. (2009). Isolation and charac-
terization of patient-derived, toxic, high mass amyloid beta-protein (Abeta)
assembly from Alzheimer disease brains. J. Biol. Chem. 284, 32895–32905.
Ostrowitzki, S., Deptula, D., Thurfjell, L., Barkhof, F., Bohrmann, B., Brooks,
D.J., Klunk, W.E., Ashford, E., Yoo, K., Xu, Z.X., et al. (2012). Mechanism of
amyloid removal in patients with Alzheimer disease treated with ganteneru-
mab. Arch. Neurol. 69, 198–207.
Paule, M.G., Bushnell, P.J., Maurissen, J.P., Wenger, G.R., Buccafusco, J.J.,
Chelonis, J.J., and Elliott, R. (1998). Symposium overview: the use of delayedCematching-to-sample procedures in studies of short-term memory in animals
and humans. Neurotoxicol. Teratol. 20, 493–502.
Paulson, J.B., Ramsden, M., Forster, C., Sherman, M.A., McGowan, E., and
Ashe, K.H. (2008). Amyloid plaque and neurofibrillary tangle pathology in a reg-
ulatable mouse model of Alzheimer’s disease. Am. J. Pathol. 173, 762–772.
Perez-Nievas, B.G., Stein, T.D., Tai, H.C., Dols-Icardo, O., Scotton, T.C., Bar-
roeta-Espar, I., Fernandez-Carballo, L., de Munain, E.L., Perez, J., Marquie,
M., et al. (2013). Dissecting phenotypic traits linked to human resilience to
Alzheimer’s pathology. Brain 136, 2510–2526.
Qiang, W., Yau, W.M., Luo, Y., Mattson, M.P., and Tycko, R. (2012). Antipar-
allel b-sheet architecture in Iowa-mutant b-amyloid fibrils. Proc. Natl. Acad.
Sci. USA 109, 4443–4448.
Reed, M.N., Hofmeister, J.J., Jungbauer, L., Welzel, A.T., Yu, C., Sherman,
M.A., Lesne´, S., LaDu, M.J., Walsh, D.M., Ashe, K.H., and Cleary, J.P.
(2011). Cognitive effects of cell-derived and synthetically derived Ab
oligomers. Neurobiol. Aging 32, 1784–1794.
Rinne, J.O., Brooks, D.J., Rossor, M.N., Fox, N.C., Bullock, R., Klunk, W.E.,
Mathis, C.A., Blennow, K., Barakos, J., Okello, A.A., et al. (2010). 11C-PiB
PET assessment of change in fibrillar amyloid-beta load in patients with
Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind,
placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363–372.
Rozkalne, A., Spires-Jones, T.L., Stern, E.A., and Hyman, B.T. (2009). A single
dose of passive immunotherapy has extended benefits on synapses and
neurites in an Alzheimer’s disease mouse model. Brain Res. 1280, 178–185.
Serrano-Pozo, A., Frosch, M.P., Masliah, E., and Hyman, B.T. (2011). Neuro-
pathological alterations in Alzheimer disease. Cold Spring Harb. Perspect.
Med. 1, a006189.
Sgourakis, N.G., Yau, W.M., and Qiang, W. (2015). Modeling an in-register,
parallel ‘‘iowa’’ ab fibril structure using solid-state NMR data from labeled
samples with rosetta. Structure 23, 216–227.
Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E.,
Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., et al. (2008).
Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair
synaptic plasticity and memory. Nat. Med. 14, 837–842.
Shankar, G.M., Leissring, M.A., Adame, A., Sun, X., Spooner, E., Masliah, E.,
Selkoe, D.J., Lemere, C.A., andWalsh, D.M. (2009). Biochemical and immuno-
histochemical analysis of an Alzheimer’s disease mouse model reveals the
presence of multiple cerebral Abeta assembly forms throughout life. Neuro-
biol. Dis. 36, 293–302.
Strobel, G. (2015). Biogen antibody buoyed by Phase 1 data and hungry inves-
tors. http://www.alzforum.org/news/conference-coverage/biogen-antibody-
buoyed-phase-1-data-and-hungry-investors.
Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R.,
Hansen, L.A., and Katzman, R. (1991). Physical basis of cognitive alterations
in Alzheimer’s disease: synapse loss is the major correlate of cognitive impair-
ment. Ann. Neurol. 30, 572–580.
Tycko, R. (2011). Solid-state NMR studies of amyloid fibril structure. Annu.
Rev. Phys. Chem. 62, 279–299.
van Haaren, F., van Zijderveld, G., van Hest, A., de Bruin, J.P., van Eden, C.G.,
and van de Poll, N.E. (1988). Acquisition of conditional associations and oper-
ant delayed spatial response alternation: effects of lesions in the medial
prefrontal cortex. Behav. Neurosci. 102, 481–488.
Westerman, M.A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawara-
bayashi, T., Younkin, L.H., Carlson, G.A., Younkin, S.G., and Ashe, K.H.
(2002). The relationship between Abeta and memory in the Tg2576 mouse
model of Alzheimer’s disease. J. Neurosci. 22, 1858–1867.
Wright, A.L., Zinn, R., Hohensinn, B., Konen, L.M., Beynon, S.B., Tan, R.P.,
Clark, I.A., Abdipranoto, A., and Vissel, B. (2013). Neuroinflammation and
neuronal loss precede Ab plaque deposition in the hAPP-J20 mouse model
of Alzheimer’s disease. PLoS ONE 8, e59586.
Wu, J.W., Breydo, L., Isas, J.M., Lee, J., Kuznetsov, Y.G., Langen, R., and
Glabe, C. (2010). Fibrillar oligomers nucleate the oligomerization of monomeric
amyloid beta but do not seed fibril formation. J. Biol. Chem. 285, 6071–6079.ll Reports 11, 1760–1771, June 23, 2015 ª2015 The Authors 1771
